Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.
Also called NCT02885857
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,500 participants
- Sponsor
- Chen Xiangmei
- Registry
-
NCT02885857
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02885857. Allocation not applicable; no masking; primary purpose treatment. Start 2015-06 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Shenyan Kangfu Tablet
- Lead sponsor
- Chen Xiangmei
- Collaborator
- Tianjin TongRenTang Group Co., Ltd.
Record details
- Record id
cardio:ct-nct02885857- Content hash
4ee2085f0dfacd9a643eea5693c15965b1a5529f69c47ce58c0b06e4f17533be